AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Myriad Genetics Names Ben Wheeler as New CFO
ByAinvest
Monday, Aug 18, 2025 5:03 pm ET1min read
Myriad Genetics has appointed Ben Wheeler as its new CFO, effective August 16, 2025. Wheeler has been with the company since 2011 and most recently served as CFO of Operations since 2022. Outgoing CFO Scott Leffler will move into a consulting role.
Myriad Genetics, Inc. (NASDAQ: MYGN), a leading molecular diagnostic testing and precision medicine company, has appointed Ben Wheeler as its new Chief Financial Officer (CFO), effective August 16, 2025. Wheeler has been with the company since 2011, holding various roles including assistant controller, vice president, corporate controller, senior vice president, accounting, and CFO, operations since 2022 [1].The outgoing CFO, Scott Leffler, who has been in the role since January 2024, will transition to a consulting role serving the CEO and the Board of Directors through September 2, 2025 [1]. Leffler's departure is part of a broader executive reshuffle aimed at streamlining operations and aligning the company's financial strategy with its long-term growth objectives.
Wheeler's extensive tenure with Myriad and his proven track record in financial leadership positions him to lead the company's finance team effectively. "I'm excited for this opportunity to lead the finance team and play a pivotal role in advancing Myriad's mission and long-term growth strategy," said Mr. Wheeler [1].
The company has reaffirmed its financial guidance for the full-year 2025, as announced during its second quarter 2025 earnings call on August 5, 2025 [1]. This guidance reflects Myriad's commitment to maintaining its profitable growth trajectory despite the ongoing challenges in the healthcare sector.
Myriad Genetics is dedicated to developing and offering molecular tests that assess the risk of developing disease or disease progression and guide treatment decisions across various medical specialties. The company's mission is to significantly improve patient care and lower healthcare costs through molecular insights [2].
References:
[1] https://investor.myriad.com/news-releases/news-release-detail/26586/
[2] https://www.nasdaq.com/articles/myriad-genetics-appoints-ben-wheeler-chief-financial-officer
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet